DK0982302T3 - Delta-6,7-taxolers antineoplastiske anvendelse og farmaceutiske sammensætninger, der indeholder dem - Google Patents

Delta-6,7-taxolers antineoplastiske anvendelse og farmaceutiske sammensætninger, der indeholder dem

Info

Publication number
DK0982302T3
DK0982302T3 DK99118034T DK99118034T DK0982302T3 DK 0982302 T3 DK0982302 T3 DK 0982302T3 DK 99118034 T DK99118034 T DK 99118034T DK 99118034 T DK99118034 T DK 99118034T DK 0982302 T3 DK0982302 T3 DK 0982302T3
Authority
DK
Denmark
Prior art keywords
substd
opt
nhcoocme3
substits
succinyl
Prior art date
Application number
DK99118034T
Other languages
Danish (da)
English (en)
Inventor
Roy A Johnson
Robert C Kelly
Harvey I Skulnick
Eldon G Nidy
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1993/011827 external-priority patent/WO1994013655A1/fr
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DK0982302T3 publication Critical patent/DK0982302T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99118034T 1993-06-11 1994-06-03 Delta-6,7-taxolers antineoplastiske anvendelse og farmaceutiske sammensætninger, der indeholder dem DK0982302T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7633793A 1993-06-11 1993-06-11
US12297493A 1993-09-17 1993-09-17
PCT/US1993/011827 WO1994013655A1 (fr) 1992-12-15 1993-12-13 7-HALO ET 7β,8β-METHANO-TAXOLS, LEUR UTILISATION ANTINEOPLASTIQUE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Publications (1)

Publication Number Publication Date
DK0982302T3 true DK0982302T3 (da) 2004-08-02

Family

ID=26757982

Family Applications (3)

Application Number Title Priority Date Filing Date
DK99118034T DK0982302T3 (da) 1993-06-11 1994-06-03 Delta-6,7-taxolers antineoplastiske anvendelse og farmaceutiske sammensætninger, der indeholder dem
DK94920688T DK0703909T3 (da) 1993-06-11 1994-06-03 Delta6,7-taxoler, antineoplastisk anvendelse og farmaceutiske præparater indeholdende dem
DK99118033T DK0982301T3 (da) 1993-06-11 1994-06-03 Delta 6,7-taxoler antineoplastisk anvendelse og farmaceutiske præparater indeholdende disse

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK94920688T DK0703909T3 (da) 1993-06-11 1994-06-03 Delta6,7-taxoler, antineoplastisk anvendelse og farmaceutiske præparater indeholdende dem
DK99118033T DK0982301T3 (da) 1993-06-11 1994-06-03 Delta 6,7-taxoler antineoplastisk anvendelse og farmaceutiske præparater indeholdende disse

Country Status (18)

Country Link
US (2) US5965739A (fr)
EP (3) EP0982302B1 (fr)
JP (1) JPH09511212A (fr)
AT (3) ATE249448T1 (fr)
AU (1) AU7138894A (fr)
CA (1) CA2161328A1 (fr)
DE (3) DE69424166T2 (fr)
DK (3) DK0982302T3 (fr)
ES (3) ES2145829T3 (fr)
GR (1) GR3033836T3 (fr)
IL (1) IL109957A (fr)
LV (2) LV12692B (fr)
NZ (2) NZ268475A (fr)
PT (3) PT982302E (fr)
SI (2) SI0703909T1 (fr)
TW (1) TW401407B (fr)
WO (1) WO1994029288A1 (fr)
ZA (1) ZA944034B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998656A (en) * 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
FR2696460B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
US5380751A (en) * 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
CA2109861C (fr) * 1992-12-04 1999-03-16 Shu-Hui Chen Paclitaxels modifies en 6,7
FR2721025B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721026B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
IT1275936B1 (it) * 1995-03-17 1997-10-24 Indena Spa Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
CA2170661A1 (fr) * 1995-03-22 1996-09-23 John K. Thottathil Methodes pour la preparation de taxanes a l'aide d'oxazolidines comme produits intermediaires
US5780653A (en) * 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
EP1114815B1 (fr) * 1996-05-08 2004-09-29 PHARMACIA & UPJOHN COMPANY Procédé de préparation de taxol
PL329637A1 (en) 1996-05-08 1999-04-12 Upjohn Co Taxol obtained method
ATE302599T1 (de) 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5977386A (en) * 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US5912264A (en) * 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6017935A (en) * 1997-04-24 2000-01-25 Bristol-Myers Squibb Company 7-sulfur substituted paclitaxels
US6150537A (en) 1997-12-12 2000-11-21 Emory University Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents
US6235776B1 (en) 1998-11-12 2001-05-22 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
US6235782B1 (en) 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
BR0013866A (pt) * 1999-09-09 2002-05-14 Univ California Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos
EP2289549A3 (fr) 1999-10-01 2011-06-15 Immunogen, Inc. Des immunoconjugués pour le traitement des cancers.
US6414015B1 (en) * 2000-01-28 2002-07-02 Utah State University Laulimalide microtubule stabilizing agents
US6649632B2 (en) * 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
IL145640A (en) * 2000-02-02 2007-02-11 Univ Florida State Res Found Texans are converted to C10 in myamloxy as anti-cancer agents
JP2003521514A (ja) 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 抗腫瘍剤としてのc10ヘテロ置換アセテートタキサン
JP2003522171A (ja) 2000-02-02 2003-07-22 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 抗腫瘍剤としてのc10カーボネート置換タキサン
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
RU2265019C2 (ru) 2000-02-02 2005-11-27 Флорида Стейт Юниверсити Рисерч Фаундейшн, Инк. Таксаны, фармацевтические композиции, способы ингибирования
US6362217B2 (en) 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
CA2410632A1 (fr) 2000-06-22 2001-12-27 David S. Garvey Taxanes nitroses et nitrosyles, compositions et procedes d'utilisation
HUP0302599A3 (en) 2000-09-22 2005-05-30 Bristol Myers Squibb Co Method for reducing toxicity of combined chemotherapic compositions
US6726923B2 (en) 2001-01-16 2004-04-27 Vascular Therapies, Llc Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts
DK1383754T3 (da) * 2001-03-23 2011-04-04 Scinopharm Taiwan Ltd Fremgangsmåde til syntetisering af taxanderivater
CA2354478A1 (fr) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. Taxanes substitues avec un carbonate en c10
ATE431343T1 (de) * 2002-10-09 2009-05-15 Chatham Biotec Ltd Thio-analoga von paclitaxel und deren vorprodukte
US7064980B2 (en) * 2003-09-17 2006-06-20 Sandisk Corporation Non-volatile memory and method with bit line coupled compensation
SV2006002010A (es) * 2004-02-13 2006-08-23 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
JP2007527432A (ja) 2004-03-05 2007-09-27 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド C7ラクチルオキシ置換タキサン
EP1848423A4 (fr) * 2005-02-14 2008-12-31 Univ Florida State Res Found Compositions de taxane a substitution cyclopropyl ester en c10
US20100069643A1 (en) * 2005-12-21 2010-03-18 Mcchesney James D Convergent Process for the Synthesis of Taxane Derivatives
ITMI20062479A1 (it) * 2006-12-21 2008-06-22 Indena Spa Processo per la preparazione di secotassani
ES2389518T3 (es) 2008-01-18 2012-10-26 Indena S.P.A. Formas sólidas de ortataxel
US8242166B2 (en) * 2008-03-31 2012-08-14 Florida State University Research Foundation, Inc. C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes
WO2011134067A1 (fr) * 2010-04-29 2011-11-03 6570763 Canada Inc. Nouvelle molécule d'acides aminés et ses utilisations
CN101863862B (zh) * 2010-06-18 2012-01-11 云南汉德生物技术有限公司 一种工业半合成紫杉醇的方法
CN103980232A (zh) * 2014-06-05 2014-08-13 北京诺普德医药科技有限公司 10-乙酰基多西紫杉醇及其用途
CN111138386A (zh) * 2019-12-30 2020-05-12 重庆市碚圣医药科技股份有限公司 一种多西他赛的半合成方法
CN115260130A (zh) * 2022-07-07 2022-11-01 上海卓鼎生物技术有限公司 一种10-脱乙酰基紫杉醇的制备方法
CN116462643A (zh) * 2023-03-29 2023-07-21 无锡贝塔医药科技有限公司 一种氘或氚标记的多西他赛的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
EP0366841A1 (fr) * 1988-11-03 1990-05-09 Dresser-Rand Company Crosse de bielle et montage du tourillon de crosse de bielle
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5175315A (en) * 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
CA2023645C (fr) * 1989-08-23 2002-03-26 Jean-Noel Denis Procede pour la preparation enantioselective de derives de la phenylisoserine
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
FR2658513B1 (fr) * 1990-02-21 1994-02-04 Rhone Poulenc Sante Procede de preparation de l'acide cis-beta-phenylglycidique-(2r,3r).
FR2658510B1 (fr) * 1990-02-21 1992-04-30 Rhone Poulenc Sante Nouveau derive de la beta-phenylisoserine, sa preparation et son emploi.
FR2662440B1 (fr) * 1990-05-22 1992-07-31 Rhone Poulenc Sante Procede de preparation stereoselective de derives de la phenylisoserine.
FR2662441B1 (fr) * 1990-05-22 1992-10-23 Rhone Poulenc Sante Procede de preparation enantioselective de derives de la phenylisoserine.
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2679230B1 (fr) * 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
US5250683A (en) * 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5227400A (en) * 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
FR2687151B1 (fr) * 1992-02-07 1994-03-25 Rhone Poulenc Rorer Sa Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
ATE136460T1 (de) * 1992-07-01 1996-04-15 Bristol Myers Squibb Co Fluor-taxole mit antitumor-wirkung
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696459B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696460B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696464B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
US5380751A (en) * 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
CA2109861C (fr) * 1992-12-04 1999-03-16 Shu-Hui Chen Paclitaxels modifies en 6,7
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
NZ330671A (en) 2000-01-28
IL109957A0 (en) 1994-10-07
IL109957A (en) 2001-01-11
DE69433146T2 (de) 2004-06-09
EP0982302A2 (fr) 2000-03-01
AU7138894A (en) 1995-01-03
EP0982302A3 (fr) 2000-07-19
DK0982301T3 (da) 2003-12-08
EP0982301B1 (fr) 2003-09-10
EP0982302B1 (fr) 2004-04-14
US5965739A (en) 1999-10-12
EP0703909B1 (fr) 2000-04-26
EP0982301A2 (fr) 2000-03-01
JPH09511212A (ja) 1997-11-11
PT982302E (pt) 2004-07-30
PT982301E (pt) 2004-02-27
WO1994029288A1 (fr) 1994-12-22
GR3033836T3 (en) 2000-10-31
DE69424166T2 (de) 2000-10-05
ATE249448T1 (de) 2003-09-15
NZ268475A (en) 1998-08-26
DK0703909T3 (da) 2000-09-11
TW401407B (en) 2000-08-11
ATE192147T1 (de) 2000-05-15
LV13319B (en) 2005-08-20
SI0703909T1 (en) 2000-08-31
DE69433715T2 (de) 2005-03-24
SI0982302T1 (en) 2004-08-31
US5556878A (en) 1996-09-17
ZA944034B (en) 1995-12-08
ATE264316T1 (de) 2004-04-15
EP0703909A1 (fr) 1996-04-03
DE69433715D1 (de) 2004-05-19
ES2205663T3 (es) 2004-05-01
DE69433146D1 (de) 2003-10-16
CA2161328A1 (fr) 1994-12-22
DE69424166D1 (de) 2000-05-31
ES2219968T3 (es) 2004-12-01
PT703909E (pt) 2000-10-31
ES2145829T3 (es) 2000-07-16
EP0982301A3 (fr) 2000-11-08
LV12692B (lv) 2001-09-20
LV12692A (lv) 2001-07-20

Similar Documents

Publication Publication Date Title
DK0982302T3 (da) Delta-6,7-taxolers antineoplastiske anvendelse og farmaceutiske sammensætninger, der indeholder dem
FI941649A (fi) Retroviirusproteaasi-inhibiittoreina käytettäviä syklisiä ureoita ja analogeja
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
SE9102462D0 (sv) New isosteric peptides
FI915282A (fi) Mono-n-substituerade 1,4,7,10-tetra -azacyklododekanderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska aemnen.
DE59706313D1 (de) Acylierte n-hydroxymethyl thalidomid-prodrugs mit immunomodulatorischer wirkung
FI940075A (fi) Menetelmä bakkatiini-III- ja 10-desasetyylibakkatiini-III-johdannaisten valmistamiseksi
FI943142A (fi) Amidi- ja ureajohdannaiset, joilla on veren korkeita kolesteroliarvoja vastustava vaikutus, niiden valmistus ja terapeuttiset käytöt
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
FI905943A (fi) Isotinderivat, deras framstaellning och anvaendning.
ATE58135T1 (de) 1,3-oxathianderivate.
FI844552A0 (fi) Aralkyl(aryletynyl)aralkyl-aminer och deras anvaendning som blodkaerlsutvidgande och blodtryckssaenkande medel.
JPS55336A (en) Preparation of amine amide compound
DK0494621T3 (da) Substitueret alkensyre og derivater deraf
ATE95172T1 (de) Cyclopropanthiocarbonsaeureamide.
TH50956A3 (th) อนุพันธ์ฟีนิลไกลซีน
JPS56142260A (en) 2-azetidinone and its preparation
NO950255L (no) Anvendelse av alfa,omega-dikarboksylsyrer som fibrinogenreduserende midler
TH15149EX (th) " สารประกอบอินทรีย์ "